Business

Bionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis

SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new

articleBionano Genomics, Inc.March 15, 20234/company/bionano-genomics-inc/news/bionano-laboratories-expands-its-clinical-testing-menu-with-launch-of-ogm-based-laboratory-developed-tests-ldts-for-prenatal-and-postnatal-analysis
Bionano Laboratories Expands its Clinical Testing Menu with Launch of OGM-Based Laboratory Developed Tests (LDTs) for Prenatal and Postnatal Analysis

About this update from Bionano Genomics, Inc.

[{"type":"text","content":"SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- Bionano Laboratories today announced the expansion of its clinical testing menu with the launch of two new laboratory developed tests (LDTs) based on optical genome mapping (OGM), OGM-DxTM Postnatal Whole Genome SV and OGM-DxTM Prenatal Whole Genome SV. These LDTs offer a genome-wide assessment of structural variants (SVs) and provide comprehensive testing for most common and rare chromosomal abnormalities. OGM-DxTM Postnatal Whole Genome SV tests peripheral blood samples from individuals who have diagnoses including but not limited to autism spectrum disorder (ASD), intellectual disability, developmental delay, epilepsy and rare undiagnosed genetic disease. The OGM-DxTM Postnatal Whole Genome SV report will include a whole genome analysis of SVs and will screen for the common CGG expansion in the FMR1 gene that may indicate Fragile X syndrome. OGM-DxTM Prenatal Whole Genome SV may be indicated for fetuses where a genetic anomaly is suspected, including abnormal ultrasound or positive non-invasive prenatal screening (NIPS), previous child with chromosomal abnormality and history of recurrent pregnancy loss. The reports from this LDT will include a whole genome analysis to assess for SVs of diagnostic and prognostic value. “We are pleased to see the launch of Bionano Laboratories' LDTs for postnatal and prenatal analysis, which can assist patients in their diagnostic and prognostic journey. These LDTs are designed to provide a comprehensive evaluation of genome wide SVs that we believe will assist clinicians in assessing the best potential medical management for their patients,” stated Justin Leighton, vice president of laboratory business at Bionano Laboratories. About Bionano Laboratories: Bionano Laboratories provides access to genetic answers and support utilizing cutting-edge technologies to advance the way you see the genome. Our clinical services offer a genetic testing experience that combines a comprehensive testing portfolio with thoughtful and accessible support options for the diagnostic journey. Bionano Laboratories also offers direct access to optical genome mapping for applications across basic, translational and clinical research. For more information, visit www.bionanolaboratories.com About Bionano Genomics Bionano Genomics is a provider of genome analysis solutions t...

More updates from Bionano Genomics, Inc.